U.S., March 5 -- ClinicalTrials.gov registry received information related to the study (NCT06856343) titled 'REBECCA Real-world Early BrEast CanCer mAnagement' on Dec. 12, 2024.
Brief Summary: This is a French observational, national, multicenter prospective cohort study of patients with HER2-negative eBC treated with olaparib at their physician's discretion.
Study Start Date: Dec. 30, 2024
Study Type: OBSERVATIONAL
Condition:
Breast Cancer
Recruitment Status: RECRUITING
Sponsor: AstraZeneca
Published by HT Digital Content Services with permission from Health Daily Digest....